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ABSTRACT 
Assuming that polyethylene glycol (PEG)-conjugated or PEGylated nanocarriers always offer outstanding physicochemical properties and 
pharmacokinetics profiles when compared to non-PEGylated ones, is not always accurate. For example, drug-loaded PEGylated nanocarriers for the 
treatment of cancer will not magically escape the reticuloendothelial system (RES) sequestration and clearance, benefit from the enhanced 
permeability and retention (EPR) effect of the tumor leaky vasculature and preferentially accumulate in the target tissue or cells. This is too good to 
be true. In this review, several drawbacks of PEGylation will be discussed; for example, how PEGylation can give rise to unfavourable 
physicochemical characteristics (e. g. particle size and release patterns) and post in vivo administration limitations of the formulated nanocarriers 
(e. g. limited evasion of RES uptake, development of hypersensitivity reactions, reduced intracellular accumulation and interference with the 
subcellular processing of nanocarriers necessary to produce the intended pharmacological effect). 
This review aims at providing better understanding of the pros and cons of PEGylation, encouraging the use of PEGylation with caution, avoiding the 
assumption that PEGylation will provide all advantages needed to deliver nanocarriers to the target tissue and looking for alternatives to optimize 
nanocarriers’ utilization especially in the delivery of chemotherapeutic agents for the treatment of different types of cancer. This review comprises 
a summary of some of the reported literature between 2013 and 2018 using different search engines; PubMed, Science Direct and Google Scholar, 
and the keywords listed below. 
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PEGylation, or the use of PEG, is one of the most common 
approaches utilized for improving nanocarriers’ e. g. nanoparticles 
(NPs’) or nanovesicles’ (NVs’) properties for in vivo administration. 
PEG, as a hydrophilic biocompatible stealth polymer, can decrease 
NPs sequestration by the RES organs (liver, spleen, kidneys). It 
prevents adsorption of proteins (opsonins) that tag the NPs or NVs 
to be engulfed by phagocytic cells in a process named opsonisation 
by providing steric hindrance preventing their interaction with 
macrophages necessary for the process of phagocytosis [1–5].  
A closer insight to the mechanism by which PEG extends circulation 
half-life revealed that PEG could preferentially bind to other 
proteins that function as dysopsonins, which are proteins capable of 
preventing opsonisation or other protein fragments in place of 
opsonins. In one study, PEGylated lipoplexes have shown the higher 
extent of serum protein (but not opsonins) binding compared to 
non-PEGylated lipoplexes [6]. 
Also, PEG is a non-ionic (neutral) polymer that can mask surface 
charge and develop a near-zero zeta potential which eventually 
reduces non-specific interaction with macrophages and favour long 
circulation time in blood [7–10]. While highly charged, positive or 
negative, or hydrophobic NPs were found to attract complement 
proteins and be highly sequestered by RES organs. Positively 
charged NPs have even showed the highest extent of sequestration 
by RES organs; where they preferentially interact with negatively 
charged plasma proteins leading to higher RES uptake [9, 11].  
Therefore, PEG can increase blood circulation time and reduce 
sequestration in the organs of the RES making NPs more available 
for uptake by their target organs or tissues e. g. tumor tissues [1–4, 
12]. In other words, long-circulating nanocarriers have higher 
chance to benefit from the EPR promoted by the tumor leaky 
vasculature [4, 13–15].  
Another interesting advantage for the PEGylated nanocarriers is their 
high ability to cross the blood-brain barrier (BBB) and accumulate in 
brain tissue more effectively than non-PEGylated ones possibly by 
transcytosis or receptor-mediated endocytosis mechanisms which need 
further to be elaborated. Diffusion through the brain parenchyma has 
also turned out to be a function of PEG coating density; i.e. the higher the 
PEG coating density, the higher the brain parenchymal diffusion [4, 16–
19]. In this regard, PEGylated nanocarriers have shown enhanced 
accumulation in pathological conditions characterized by BBB 
hyperpermeability e. g. gliosarcoma and multiple sclerosis (MS)-induced 
inflammation and brain tumors-induced EPR effect [16]. 
For these advantages, PEG has been regarded as a gold standard 
polymer in various applications and could not be neglected; 
however, on the other hand, many drawbacks have been reported 
over the years that could limit its applications (fig. 1);  
Major hurdles of PEGylation 
PEGylation that has been widely used to improve the physical and 
chemical properties of nanocarriers showed unfavourable profiles of an 
abrupt release of the loaded cargos before or right after in vivo 
administration, even before NPs sufficiently accumulate in target tissues.  
Also, particle size enlargement has been observed on comparison of 
PEGylated and non-PEGylated nanocarriers which produced a 
reversed effect on the intended RES evasion and accumulation in 
tumor tissue by the EPR effect [6].  
Deeper analysis of the effect of PEGylation on the cellular and 
subcellular fate showed reduced uptake and interference with NPs 
processing which could hinder the optimized pharmacological effect 
of the loaded drug [13]. Also, there has been evidence of the 
occurrence of PEG-containing vacuoles in cells. Reports so far also 
show the potential risk of PEG itself being a non-biodegradable 
polymer that can produce an immune response or cause 
hypersensitivity where PEG could generate antibodies that can 
neutralize their efficacy upon repeated administration [6].  
Also, PEG synthesis and purification are difficult processes that give 
rise to an inherent polydispersity of the polymer which eventually 
causes batch-to-batch variability [20]. 
International Journal of Applied Pharmaceutics 
ISSN- 0975-7058                              Vol 10, Issue 5, 2018 
Sebak et al. 




Fig. 1: Main drawbacks of PEGylation of nanocarriers 
 
Unfavorable physicochemical properties of PEGylated nanocarriers 
PEGylation was reported to affect the physicochemical properties of 
NPs adversely causing enlargement of particle size-that could 
enhance RES uptake especially with large molecular weight PEG-and 
abrupt release of the drug loads from NPs over a short period of 
time. For example, PEGylated liposomes loaded with doxorubicin 
have shown a faster release of drug cargos than the non-PEGylated 
counterparts, where 90% of the loaded doxorubicin was released in 
3 h post intravenous (IV) administration while the emptied 
liposomes were still circulating in blood before reaching the target 
site. This made the assumption that the loaded drug cargo is 
released after being up-taken by target cells not accurate. Similarly, 
the release of morphine from poly (L-lactide) or PLA-PEG block 
copolymer particles have shown to be much faster than release from 
PLA polymer ones. Also, the release rate has been shown to be a 
function of PEG percentage (%) in the copolymer i.e. the initial burst 
release is more evident in particles with PEG content of 5% 
compared to 3%. While particles containing 0-1% of PEG showed no 
burst release, but rather a continuous sustained release over time. 
Upon estimating the T80%, which represents the time when the 
cumulative release percentage of morphine reached about 80%, 
PEG-free particles showed around 15 and 30 times longer T80%
RES evasion capacity not as expected or even worsened and 
reversed 
 than 
particles containing 3 and 5% of PEG respectively. This reflects that 
loaded cargos could be released from PEG-containing particles before 
degradation of the polymer. In other words, particles could become 
empty of the loaded cargos while they are still in circulation before 
their degradation. Moreover, a similar trend was reported for 
PEGylated and non-PEGylated poly (lactic-co-glycolic acid) (PLGA) and 
PLA NPs. Faster release profiles of hydrophilic drugs loaded in 
PEGylated NPs could be attributed to the hydrophilicity of PEG chains 
at the surface of the nanocarriers which act to attract water resulting 
in pronounced wetting/hydration of PEGylated NPs [9, 10, 21, 22].  
As reported earlier in the advantages of PEGylation, the hydrophilic 
polymer provides steric hindrance and masking of surface charge 
that prevents adsorption of tagging proteins (opsonisation) which is 
a prerequisite of uptake by RES macrophages; however, PEGylation 
capacity of prevention of opsonisation has shown to be limited, and 
eventual opsonisation and RES clearance has been repeatedly 
reported. In one study, for example, temoporfin (photosensitizer 
used in photodynamic cancer therapy) was loaded in both PEGylated 
and non-PEGylated PLGA NPs and followed for in vivo behaviour. It 
has been reported that similar amounts of both NPs accumulated in 
the spleen and that the RES tissue distribution differed only slightly 
between PEGylated and non-PEGylated NPs showing inefficiency of 
PEGylation in RES evasion [23].  
In another study, PEGylation of thiolated gelatin was observed to 
reduce mean residence time (MRT) and half-life of NPs in blood. In 
other words, the majority of NPs were cleared from the blood by 
circulating phagocytes and tissue macrophages (hepatic kupffer cells 
and macrophages in the spleen) and the NPs eventually accumulated 
in the liver and spleen [10]. A similar trend was reported for 
PEGylated and albumin-conjugated PEGylated liposomes, where 
results showed that albumin conjugation produced the longest 
circulation time [24]. Many factors control the effect of PEGylation 
on NPs’ fate; these include the molecular weight, PEG polymer 
identity, composition and hydrophobicity, density and stability of 
the PEG in the coating layer, NP core properties, and repeated 
administration. These criteria if not properly controlled lead to 
unfavourable effects upon PEG coating [6, 13, 25–27].  
The limited RES evasion capacity by PEGylation has been attributed 
to many phenomena; most importantly, size enlargement of 
nanocarriers, desorption of PEG from nanocarriers’ surfaces and 
production of anti-PEG antibodies and development of an immune 
response that causes accelerated blood clearance (ABC) of 
PEGylated nanocarriers. These are explained in detail as follows;  
PEGylation causes enlargement of particle size 
Formulations possessing average particle size ≤ 150-200 nm were 
reported to be suitable for IV application [7, 28, 29]; being large enough 
to avoid filtration in the kidney, and small enough to avoid sequestration 
in the RES organs (liver, spleen, kidneys), and suitable for selective 
accumulation and retention in tumor by EPR effect [30–34]. 
In one study, PEGylation of PLGA NPs led to a larger particle size 
that had an effect on the pharmacokinetics of NPs and accounted for 
the abnormal decrease in the MRT of NPs in blood [10]. This means 
evasion of RES by PEG is not absolute. Larger size conferred by PEG 
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layer could make them more accessible to RES organs than the 
smaller non-PEGylated PLGA NPs [9]. 
In another study, increasing the % of PEG in PLGA NPs from 0% to 
9% to 15% increased particle size from ~740 nm to 1170 nm to 
1995 nm respectively [35]. A similar observation was recorded in 
chitosan NPs; where PEGylated chitosan NPs possessed larger 
particle size (~290 nm) than non-PEGylated ones (~200 nm) [36]. 
Also, PEG coating of nanostructured lipid carriers (NLCs) led to size 
enlargement from (~72 nm) to (~92 nm) [37].  
Insufficiency or desorption of PEG layer 
As reported earlier in the advantages of PEGylation, the hydrophilic 
polymer provides steric hindrance that prevents adsorption of 
tagging proteins (opsonisation) which is a prerequisite of uptake by 
RES macrophages; however, it has also been observed that PEG 
polymers could also desorb, leaving holes in surface coverage where 
opsonins can bind [38] or not provide full prevention of 
opsonisation at low density of PEG or using low molecular weight 
polymer. For example, with 5 nm gold NPs, the protective effect of 
PEG diminishes within hours [39].  
Immunogenicity of PEG 
PEG, the long-believed polymer to be non-antigenic could develop an 
immune response resulting in ABC of PEG-modified materials e. g. 
PEGylated proteins, liposomes, micelles, and biodegradable and non-
biodegradable nanocarriers. Where an anti-PEG antibody could be 
formed that results in the faster elimination of the second or further IV 
injected dose in animal studies and clinical settings [39]. This has been 
clarified by the formation of immune complexes which can be rapidly 
bound and cleared by macrophages via Fc receptor-mediated 
phagocytosis [40]. 
The ABC phenomenon is believed to result from anti-PEG IgM 
antibody produced by the spleen in response to a previously-
administered dose. This type of antibody is, however, unable to 
solely promote sequestration by RES macrophages. However, these 
antibodies were hypothesized to bind to the second injected dose of 
PEG conjugates and form a complex with other serum components 
eventually promoting sequestration by RES [6, 13]. For instance, the 
second injection of PEGylated liposomes witnessed reduced 
circulation time and increased hepatic and splenic accumulation in 
comparison to the first injected dose of the same formulation in the 
same animal [6]. Moreover, anti-PEG antibodies of both IgG and IgM 
isotypes were found in 25% of 250 healthy blood donors. This 
extraordinary evidence of anti-PEG antibodies was explained by the 
increasing exposure of the general population to PEG in different 
cosmeceutical and pharmaceutical products for many years [41]. 
Other reports show the incidence of anti-PEG antibodies in the range 
of 0.4% to 36% in naïve individuals [40].  
In another study, a more severe adverse effect to the 
immunogenicity of PEG, hypersensitivity, has been observed 
clinically where three cases (0.002% of the treated patients with 
advanced coronary artery disease) administered a commercial PEG-
containing contrast agent, SonoVue, developed life-threatening 
anaphylactic shock [6, 15, 42]. 
The loss of activity of PEGylated pharmaceutical products upon repeated 
injection has also extended to anticancer therapeutics. PEGylated 
asparaginase is an integral part of therapy for acute lymphoblastic 
leukaemia (ALL) that is administered either intravenously (IV) or 
intramuscularly (IM). In a study, 46% of patients were reported to 
develop anti-PEG antibodies in response to IV administration that 
resulted in accelerated clearance of subsequent doses eventually causing 
silent inactivation of the treatment. In another study, 25% of patients 
were identified with pre-existing anti-PEG antibodies prior to treatment 
that could be attributed to their pre-exposure to PEG from other 
pharmaceutical or cosmeceutical products that are widely available. 
Another study showed the development of anti-PEG antibodies after IM 
administration of the PEGylated asparaginase [13, 43, 44]. 
Therefore, it could be concluded that PEG effect does not last for a 
long time, and eventually, opsonisation and clearance by RES organs 
still occur [45]. 
The prevalence of anti-PEG antibodies has shown to be higher in 
females than males; this could be explained by their higher exposure 
to PEG-containing products e. g. skin lotions, deodorant sticks, hair 
care products and face makeup products or their higher tendencies 
to have autoimmune responses [40].  
Unfavourable cellular and subcellular fate 
Another major drawback of PEGylation is the reduced intracellular 
uptake of the PEGylated NPs in comparison to non-PEGylated ones due 
to the steric hindrance caused by the projecting chains of PEG polymers 
and the hydrophilicity of NPs’ surfaces as well. In other words, neutral 
and hydrophilic NPs e. g. PEG-modified NPs show slower and lower 
internalization in target cells than both of positively and negatively 
charged ones. For example, intracellular uptake of PEGylated NPs was 
noted to drop to one-third of the uptake of non-PEGylated ones [46, 47]. 
Also, PEGylation of folic acid (FA)-targeted dendrimers has been also 
reported decreasing the tumour-specific targeting by FA [20]. 
Therefore, even that PEGylation could sometimes evade 
sequestration of drug-loaded nanocarriers by RES cells and increase 
the probability of extravasation of NPs through the tumor leaky 
vasculature, it reduces interaction with target tissues e. g. tumor 
cells, whereby PEG shields internalization by non-immune cells by 
both steric hindrance and masking of NPs surface charge required 
for optimum cellular uptake [13].  
In a similar manner, the interesting properties of PEG to enhance BBB 
crossing encouraged the application of PEGylated nanocarriers for brain 
delivery; however, it should not be neglected that there is another 
barrier that could hinder the successful delivery of therapeutic agents, 
which is the microglial cells that constitute the immune component of 
the central nervous system (CNS) itself. These cells are characterised by 
high phagocytic activity that resembles RES macrophages that could 
compete with other non-immune neural cell types for NPs’ uptake. Jenkis 
et al., 2016 have been concerned with comparison of NPs’ uptake in their 
PEGylated and non-PEGylated forms in different neural cell types; their 
findings confirmed that PEGylation reduces NPs’ uptake in all cell types; 
immune and non-immune neural cells suggesting that PEGylation evades 
non-specific cell uptake that could outweigh its advantage of BBB and 
parenchymal diffusion when applied for brain drug delivery [16]. 
The effect of PEGylation on the target cells is not limited to reduced 
uptake but extends to inhibition of endosomal escape, which results 
in significant loss of activity of the delivery systems e. g. gene and 
nucleic acid delivery systems for cancer treatment where the NPs’ 
cargos are degraded in the digestive acidic medium of the 
endolysosomal system [41].  
The detrimental effect of PEGylation extends also to the interference 
with the intracellular processing of NPs required for optimum 
release of loaded cargos to achieve the intended goals. For example, 
PEGylated nanocarriers intended for gene and siRNA delivery have 
shown reduced transfection and silencing rates that could not be 
explained solely by the previously discussed reduced uptake caused 
by PEGylation. Therefore, it was concluded that PEGylation affects 
the intracellular fate of nanocarriers after being internalized by 
target cells. In different studies, PEGylation levels as low as 0.4-0.5% 
showed a drastic decrease in transfection rates indicating that the 
therapeutic gene expression in the target cells may be significantly 
compromised by PEGylation [13].  
Non-biodegradability of PEG polymers 
Despite that PEG has been the gold standard in pharmaceuticals’ 
application for many years possessing the longest clinical track 
record amongst many other polymers and that it has been widely 
used as a biocompatible polymer, it should be noted that it is non-
biodegradable and that its ultimate fate and potential side effects 
that could arise from its accumulation need further to be elaborated. 
Also, there are concerns about its bioaccumulation in lysosomes of 
healthy tissue. Therefore, limiting the molecular weight should be 
taken into account for in vivo application [13, 48–50].  
Sebak et al. 
Int J App Pharm, Vol 10, Issue 5, 2018, 6-12 
9 
Strategies to overcome PEGylation drawbacks 
Proper selection of PEG polymer and conjugation chemistry 
There are many available approaches to overcome the PEG dilemma 
(fig. 2), for example, choosing appropriate polymers with less or no 
antigenicity and controlling the different criteria that can affect 
PEGylation outcomes e. g. PEG molecular weight, density and 
stability of the PEG coating [6, 25, 27]. In one study, branched PEG 
was shown to be the least immunogenic and antigenic when 
compared to methoxy-PEG (mPEG) and other un-branched PEG 
forms [6]. Also, a more recent study by Shimizu et al. showed that 
hydroxyl-PEG could also serve as a potential alternative to mPEG. It 
could attenuate the elicitation of the ABC phenomenon when 
conjugated to PEGylated liposomes by the production of less anti-
PEG IgM antibodies [51]. In another report, the immunogenicity of 
different PEG derivatives showed the following order; t-butoxy-PEG 
(tBu-PEG)>mPEG>hydroxyl-PEG (OH-PEG). Also, two types of anti-
PEG antibodies have been proposed; methoxy-specific and 
backbone-specific. Where OH-PEG was found to produce antibodies 
that have a similar affinity to both mPEG and OH-PEG, while mPEG 
antibodies recognize mPEG more effectively than OH-PEG [26]. 
 
 
Fig. 2: Alternative strategies to overcome PEGylation drawbacks 
 
Also, the issue of non-biodegradability of PEG could be addressed 
and solved; for example, by conjugating PEG to degradable PLA or 
poly (glycolic acid), (PGA) segments to form corresponding 
biodegradable copolymer [52, 53]. 
In the meanwhile, attempting to overcome the detrimental effect of 
PEGylation on gene and siRNA delivery, PEG has been conjugated to 
shorter lipid anchors to facilitate loaded cargos diffusion out of the 
lipid-based delivery systems. In another attempt, PEG was attached 
to site-specific cleavable linkers e. g. matrix metalloprotease (MMP)-
sensitive linkers in tumors or pH sensitive linkers to be cleaved by 
the low pH conditions encountered after cellular uptake in the 
lysosomal degradation pathway [13].  
Alternative coatings 
In another approach to overcome PEGylation dilemma, alternative 
coatings of nanocarriers have been studied. For example, NPs with 
zwitterionic coatings were found to be able to evade brain immune 
components and reduce the rate of non-specific binding for proteins 
and lipids without steric hindrance [16]. 
Moreover, 5-nm gold NPs were coated with amino acids such as lysine 
or cysteine to constitute a mixed-charge monolayer. This coating could 
prevent protein adsorption in fetal bovine serum [39, 54].  
Also, another study employed acetylation of dendrimers as an 
alternative to PEGylation. This approach offered the advantage of 
RES evasion without adding steric hindrance that could reduce the 
interaction between FA on the acetylated dendrimers and folate 
receptor on the surface of the target cells that could reduce the 
uptake of the NPs as in the case of FA-conjugated PEGylated 
dendrimers. The mechanism by which acetylation reduces RES 
clearance was hypothesized to occur by neutralizing the cationic 
surface of the dendrimers and reducing the electrostatic interactions 
with serum proteins that are required for uptake by RES 
macrophages. Acetylation is also potentially applicable for 
modification of other types of nanocarriers and possesses an added 
advantage of better control over the size and polydispersity of the 
NP compared to PEGylation [20]. 
Utilization of hyperbranched polyglycerol (HPG) as an alternative to 
the typical PEG has shown to be promising in the brain drug delivery. 
HPG showed more favourable physicochemical properties e. g. higher 
drug loading, higher NPs’ surface coverage and higher effectiveness for 
ligand conjugation and more prolonged circulation time [50,55]. HPG 
coating imparted excellent stability of magnetic Fe3O4 
Other stealth polymers such as chitosan, poly (carboxybetaine), 
polysaccharides, polypeptides, poly (vinyl alcohol) and poly (2-
oxaline) have been also investigated [25, 26]. 
NPs in cell 
culture medium. These coated NPs were nontoxic to mammalian cells 
and showed minimal uptake by macrophages. HPG also offers a 
platform for staging the NPs surfaces for active targeting [49]. 
Lipids also can be used as coatings for NPs to increase their blood 
circulation time as an alternative to PEG, producing hybrid lipid-
polymer NPs. Hybrid NPs represent a promising drug delivery 
platform that has shown controllable particle size, surface 
functionality, high drug loading yield, triggered or stimuli-
responsive drug release profile, excellent in vitro and in vivo 
stability, biocompatibility and biodegradability. Also, co-loading of 
drugs with different physicochemical properties became possible. In 
other words, the polymeric core functions to encapsulate either 
water or oil-soluble drugs and to provide robust structures, whereas 
the external lipid coat offers the following advantages; (i) acts as a 
biocompatible shield, (ii) a template for surface modifications, (iii) a 
Sebak et al. 
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barrier preventing the fast leakage of water-soluble drugs (iv) 
possesses favourable stability in serum (longer circulation times) 
and (v) good cellular accumulation and targeting ability [33, 56–61]. 
In another study, it was observed that the incorporation of 
phospholipid into polymeric NPs could significantly enhance their 
intracellular accumulation [62]. 
Utilization of markers of self; target-specific ligands 
In order to address the problem of reduced intracellular uptake by 
target cells upon PEGylation, markers of self or target-specific ligands 
e. g. FA or transferrin can be attached to the surface of the NPs in order 
to achieve active targeting (enhance cellular uptake into target tissues 
and to avoid exposure of healthy cells) and also help minimize or avoid 
complement activation [39]. Arginine-glycine-aspartic acid (RGD) 
tripeptide has also shown to improve the selectivity, binding and 
uptake of the NPs by targeted cells because of its ability to be 
recognized by integrin receptors that are ovreexpressed on tumor 
cells. This strategy can specifically enhance the limited uptake 
drawback due to steric hindrance by PEG polymers [41]. In another 
study, targeted PEGylated liposomes produced by conjugation to the 
fibronectin-mimetic peptide, PR_b, to target α5β1 in metastatic colon 
cancer, have shown better transfection efficiency than non-targeted 
ones [5]. Further optimization of PEGylated liposomes was performed 
by dual targeting; in a study, PR_b and AG86 peptides were used to 
target α5β1 and α6 β4 
The same targeting strategy could be applied to optimize the brain 
delivery of drugs in PEGylated nanocarriers. For example, PEGylated 
gold NPs, when functionalized with transferrin-specific peptide, 
showed significantly higher accumulation in brain tumor [64]. Also, 
PEGylated PLGA NPs or polymersomes when conjugated with phage 
display peptide or lactoferrin respectively showed higher brain 
accumulation [64, 65]. Dual targeting has also been employed to 
optimize brain drug delivery; where paclitaxcel was conjugated to 
cyclo-[Arg-Gly-Asp-D-Phe-Lys] peptide which can interact specifically 
with integrin receptors, overexpressed on glioma cells. This conjugate 
was further loaded into PEGylated lipid-polymer hybrid NPs [66]. 
respectively were conjugated with different 
ratios to the PEGylated liposomes and investigated for their 
internalization and transfection efficiencies in dual receptor 
expressing cancer cells. Results showed high selectivity of the 
employed nanocarrier system especially in ovarian cancer cells (SK-
OV-3) characterized by an almost equal expression of the two 
receptors [63]. 
CONCLUSION 
In conclusion, PEG has shown, for decades, the outstanding potential 
for enhancement of properties of drug delivery systems that made 
its application in pharmaceuticals and cosmeceuticals widespread. 
However, improper control of the PEGylation process gave rise to 
many drawbacks that render its application limited. Also, chronic 
exposure to PEG for many years made the immune system of 
humans and animals alert to the molecule producing antibodies; that 
limit the efficacy of the administered drug in most of the times and 
could give rise to more serious side effects e. g. anaphylactic shock. 
Therefore, PEGylation should be used with great caution. Also, 
looking for alternatives has emerged to become an ultimate 
necessity.  
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